Yahoo
NSE - Delayed Quote INR

Aurobindo Pharma Limited (AUROPHARMA.NS)

1,681.40 +21.50 (+1.30%)
At close: October 30 at 3:28:19 PM GMT+5:30
Chart Range Bar
Loading chart for AUROPHARMA.NS
  • Previous Close 1,659.90
  • Open 1,652.00
  • Bid --
  • Ask --
  • Day's Range 1,647.20 - 1,687.00
  • 52 Week Range 1,106.00 - 1,740.00
  • Volume 952,194
  • Avg. Volume 891,788
  • Market Cap (intraday) 967.44B
  • Beta (5Y Monthly) 0.03
  • PE Ratio (TTM) 26.27
  • EPS (TTM) 64.00
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield 4.00 (0.00%)
  • Ex-Dividend Date Aug 8, 2025
  • 1y Target Est 1,757.15

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

www.aurobindo.com

29,209

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

AUROPHARMA.NS
42.13%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

AUROPHARMA.NS
52.51%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

AUROPHARMA.NS
96.81%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

AUROPHARMA.NS
150.69%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 91.5B
Earnings 10.33B
Profit Margin 11.28%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
20B
40B
60B
80B
10.4%
10.6%
10.8%
11.0%
11.2%

Analyst Insights

View More

Analyst Price Targets

1,270.00 Low
1,757.15 Average
1,681.40 Current
2,000.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.63%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    349.35B

  • Net Income Avi to Common (ttm)

    37.13B

  • Diluted EPS (ttm)

    64.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    105.85B

  • Total Debt/Equity (mrq)

    21.31%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: